Atherosclerosis
Volume 188, Issue 2 , Pages 301-308 , October 2006

Dietary reversal of experimental hypercholesterolemia improves endothelial dysfunction of epicardial arteries but not of small coronary vessels in pigs

  • Katherine J.E. Sattler

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN, USA
    • ,
  • Offer Galili

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN, USA
    • ,
  • Martin Rodriguez-Porcel

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN, USA
    • ,
  • James D. Krier

      Affiliations

    • Division of Nephrology and Hypertension, Rochester, MN, USA
    • ,
  • Lilach O. Lerman

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN, USA
    • Division of Nephrology and Hypertension, Rochester, MN, USA
    • ,
  • Amir Lerman

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN, USA
    • Corresponding Author InformationCorresponding author at: Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, MN 55905, USA. Tel.: +1 507 255 4152; fax: +1 507 255 2550.

Received 18 August 2005 ,Revised 2 November 2005 ,Accepted 3 November 2005.

References 

  1. Gonzalez MA, Selwyn AP. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med. 2003;115(Suppl 8A):99S–106S
  2. Schaechinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899–1906
  3. Chan SY, Mancini GBJ, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol. 2000;42:1037–1043
  4. Rodriguez-Porcel M, Lerman LO, Holmes DR, Richardson D, Napoli C, Lerman A. Chronic antioxidant supplementation attenuates nuclear factor-κB activation and preserves endothelial function in hypercholesterolemic pigs. Cardiovasc Res. 2002;53:1010–1018
  5. Wilson SH, Caplice NM, Simari RD, Holmes DR, Carlson PJ, Lerman A. Activated nuclear factor-kappa B is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis. 2000;148:23–30
  6. Herrmann J, Gulati R, Napoli C, et al. Oxidative stress-related increase in ubiquitination in early coronary atherogenesis. FASEB J. 2003;17:1730–1732
  7. Herrmann J, Ciechanover A, Lerman LO, Lerman A. The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended. Cardiovasc Res. 2004;61:11–21
  8. Zhu XY, Rodriguez-Porcel M, Bentley MD, et al. Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. Circulation. 2004;109:2109–2115
  9. Mantha SV, Prasad M, Kalra J, Prasad K. Antioxidant enzymes in hypercholesterolemia and effects of Vitamin E in rabbits. Atherosclerosis. 1993;101:135–144
  10. Boeger RH, Bode-Boeger SM, Muegge A, et al. Supplementation of hypercholesterolaemic rabbits with l-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis. 1995;117:273–284
  11. Rodriguez-Porcel M, Lerman LO, Herrmann J, Sawamura T, Napoli C, Lerman A. Hypercholesterolemia and hypertension have synergistic deletrious effects on coronary endothelial function. Arterioscler Thromb Vasc Biol. 2003;23:885–891
  12. Wilson SH, Chade AR, Feldstein A, et al. Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolaemia. Nephrol Dial Transplant. 2003;18:703–709
  13. Wilson SH, Simari RD, Best PJM, et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol. 2001;21:122–128
  14. Stulak JM, Lerman A, Caccitolo JA, et al. Impaired renal vascular endothelial function in vitro in experimental hypercholesterolemia. Atherosclerosis. 2001;154:195–201
  15. Hasdai D, Sangiorgi G, Spagnoli LG, et al. Coronary artery apoptosis in experimental hypercholesterolemia. Atherosclerosis. 1999;142:317–325
  16. Mingnone C, Gupte SA, Iesaki T, Wolin MS. Hypoxia enhances a cGMP-independent nitric oxide relaxing mechanism in pulmonary arteries. Am J Physiol. 2003;285:L296–L304
  17. Lerman A, Webster MW, Chesebro JH, et al. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation. 1993;88:2923–2928
  18. Verhamme P, Quarck R, Hao H, et al. Dietary cholesterol withdrawal reduces vascular inflammation and induces coronary plaque stabilization in miniature pigs. Cardiovasc Res. 2002;56:135–144
  19. Chilian WM, Eastham CL, Marcus ML. Microvascular distribution of coronary vascular resistance in beating left ventricle. Am J Physiol. 1986;251:H779–H788
  20. Prasad A, Higano ST, Al Suwaidi J, et al. Abnormal coronary microvascular endothelial function in humans with asymptomatic left ventricular dysfunction. Am Heart J. 2003;146:549–554
  21. Hasegawa H, Yamamoto R, Takano H, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol. 2003;35:953–960
  22. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003;108:839–843
  23. Bonetti PO, Wilson SH, Rodriguez-Porcel M, Holmes DR, Lerman LO, Lerman A. Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering. J Am Coll Cardiol. 2002;40:546–554
  24. Stulak JM, Lerman A, Rodriguez-Porcel M, et al. Renal vascular function in hypercholesterolemia is preserved by chronic antioxidant supplementation. J Am Soc Nephrol. 2001;12:1882–1891
  25. Moncada S, Rees DD, Schulz R, Palmer RMJ. Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci USA. 1991;88:2166–2170
  26. Hsich E, Segal BH, Pagano PJ, et al. Vascular effects following homozygous disruption of p47phox: an essential component of NADPH oxidase. Circulation. 2000;101:1234–1236
  27. Batenburg WW, Garrelds IM, van Kats JP, Saxena PR, Danser AH. Mediators of bradykinin-induced vasorelaxation in human coronary microarteries. Hypertension. 2004;43:488–492
  28. Kemp BK, Cocks TM. Evidence that mechanisms dependent and independent of nitric oxide mediate endothelium-dependent relaxation to bradykinin in human small resistance-like coronary arteries. Br J Pharmacol. 1997;120:757–762
  29. Bengtsson SH, Gulluyan LM, Dusting GJ, Drummond GR. Novel isoforms of NADPH oxidase in vascular physiology and pathophysiology. Clin Exp Pharmacol Physiol. 2003;30:849–854
  30. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med. 2002;33:337–349

PII: S0021-9150(05)00728-8

doi: 10.1016/j.atherosclerosis.2005.11.009

Atherosclerosis
Volume 188, Issue 2 , Pages 301-308 , October 2006

Article Tools

* Image Usage & Resolution